Disclosures for "Rapidly Progressive Dementia and Extrapyramidal Symptoms Associated with Froin’s Syndrome due to Leptomeningeal Carcinomatosis "
-
An immediate family member of Dr. Patel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. An immediate family member of Dr. Patel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Patel has stock in Ocular Therapeutix. Dr. Patel has stock in Autolus Therapeutics . Dr. Patel has stock in Larimar Therapeutics. Dr. Patel has stock in Viking Therapeutics. An immediate family member of Dr. Patel has stock in Voyager Therapeutics. Dr. Patel has stock in Pfizer. The institution of an immediate family member of Dr. Patel has received research support from The Patient-Centered Outcomes Research Institute.
-
Dr. Holland has nothing to disclose.
-
Dr. Esch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Esch has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Esch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Esch has received research support from PCORI.